Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PALI
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more TTM periods Free account |
— | — | — | 0.76 |
Gross Profit |
— | — | — | 0.72 | |
R&D Expenses |
6.10 | 10.19 | 15.64 | 21.36 | |
SG&A Expenses |
5.35 | 7.86 | 10.86 | 14.49 | |
Operating Income |
(11.46) | (18.06) | (26.49) | (35.35) | |
Non-operating Income/Expense |
0.23 | 1.28 | 2.34 | 3.41 | |
Non-operating Interest Expenses |
0.01 | 0.01 | 0.01 | — | |
| (11.23) | (16.78) | (24.15) | (31.94) | ||
Income after Tax |
(11.23) | (16.78) | (24.15) | (31.94) | |
Dividends (Preferred) |
— | — | 0.02 | — | |
Net Income Common |
(11.23) | (16.78) | (24.15) | (31.94) | |
EPS (Basic) |
(2.12) | (0.30) | 0.12 | 0.65 | |
EPS (Diluted) |
(2.12) | (0.30) | 0.12 | 0.65 | |
Shares (Basic, Weighted) |
4.62 | 18.18 | 69.40 | 121.05 | |
Shares (Diluted, Weighted) |
4.62 | 18.18 | 69.40 | 121.05 | |
Gross Margin |
— | — | — | 95.63% | |
EBIT Margin |
0.00% | 0.00% | 0.00% | (4,681.99%) | |
EBT margin |
0.00% | 0.00% | 0.00% | (4,230.60%) | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (4,230.60%) | |
Free Cash Flow Margin |
0.00% | 0.00% | 0.00% | (2,409.27%) | |
EBITDA |
(11.45) | (18.05) | (26.49) | (35.35) | |
EBIT |
(11.46) | (18.06) | (26.49) | (35.35) | |
EPS (Diluted, from Cont. Ops) |
(1.39) | (0.30) | 0.12 | 0.65 | |
EPS (Diluted, Consolidated) |
(1.39) | (0.30) | 0.12 | 0.65 | |
EPS (Basic, Consolidated) |
(1.39) | (0.30) | 0.12 | 0.65 | |
Shares (Diluted, Average) |
5.48 | — | 56.68 | 108.33 | |
EPS (Basic, from Continuous Ops) |
(1.39) | (0.30) | 0.12 | 0.65 | |
Income from Continuous Operations |
(11.23) | (16.78) | (24.15) | (31.94) | |
Consolidated Net Income/Loss |
(11.23) | (16.78) | (24.15) | (31.94) | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | (4,681.85%) | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | (2,409.27%) |